{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T03:24:21Z","timestamp":1784690661437,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T00:00:00Z","timestamp":1670630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T00:00:00Z","timestamp":1670630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s40263-022-00976-4","type":"journal-article","created":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T11:03:12Z","timestamp":1670670192000},"page":"107-116","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["A 10-Year Observational Study of the Use, Acceptability and Effectiveness of Long-Acting Paliperidone Palmitate: Implications for Clinical Decision Making"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6303-1547","authenticated-orcid":false,"given":"Sofia","family":"Pappa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8182-0745","authenticated-orcid":false,"given":"Joshua","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2150-3419","authenticated-orcid":false,"given":"Katy","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,10]]},"reference":[{"key":"976_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32279-7","author":"SL James","year":"2018","unstructured":"James SL. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018. https:\/\/doi.org\/10.1016\/S0140-6736(18)32279-7.","journal-title":"Lancet"},{"issue":"6","key":"976_CR2","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/eip.12412","volume":"11","author":"J Immonen","year":"2017","unstructured":"Immonen J, J\u00e4\u00e4skel\u00e4inen E, Korpela H, Miettunen J. Age at onset and the outcomes of schizophrenia: a systematic review and meta-analysis. Early Interv Psychiatry. 2017;11(6):453\u201360. https:\/\/doi.org\/10.1111\/eip.12412.","journal-title":"Early Interv Psychiatry"},{"key":"976_CR3","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2147\/NDT.S96649","volume":"12","author":"HY Chong","year":"2016","unstructured":"Chong HY, Teoh SL, Wu DB, Kotirum S, Chiou CF, Chaiyakunapruk N. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Dis Treat. 2016;12:357\u201373. https:\/\/doi.org\/10.2147\/NDT.S96649 (Published 2016 Feb 16).","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"2","key":"976_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s40258-019-00530-2","volume":"18","author":"J Ride","year":"2020","unstructured":"Ride J, Kasteridis P, Gutacker N, Aragon MJ, Jacobs R. Healthcare costs for people with serious mental illness in England: an analysis of costs across primary care, hospital care, and specialist mental healthcare. Appl Health Econ Health Policy. 2020;18(2):177\u201388. https:\/\/doi.org\/10.1007\/s40258-019-00530-2.","journal-title":"Appl Health Econ Health Policy"},{"issue":"2","key":"976_CR5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/wps.20516","volume":"17","author":"CU Correll","year":"2018","unstructured":"Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry. 2018;17(2):149\u201360. https:\/\/doi.org\/10.1002\/wps.20516.","journal-title":"World Psychiatry"},{"issue":"9","key":"976_CR6","first-page":"638","volume":"39","author":"KR Patel","year":"2014","unstructured":"Patel KR, Cherian J, Gohil K, Atkinson D. Schizophrenia: overview and treatment options. P T. 2014;39(9):638\u201345.","journal-title":"P T"},{"key":"976_CR7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.schres.2020.11.011","volume":"229","author":"W Gaebel","year":"2021","unstructured":"Gaebel W, Stricker J, Hasan A, Falkai P, McIntyre JS, Kerst A. The revised DGPPN and APA schizophrenia guidelines: guideline quality and recommendations for long-term antipsychotic treatment. Schizophr Res. 2021;229:137\u20139. https:\/\/doi.org\/10.1016\/j.schres.2020.11.011 (Epub 2020 Nov 15 PMID: 33203610).","journal-title":"Schizophr Res"},{"key":"976_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2009.05.004","author":"D Novick","year":"2010","unstructured":"Novick D, Haro JM, Suarez D, Perez V, Dittmann RW, Haddad PM. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res. 2010. https:\/\/doi.org\/10.1016\/j.psychres.2009.05.004.","journal-title":"Psychiatry Res"},{"issue":"13","key":"976_CR9","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1471-244X-13-50","volume":"8","author":"R Emsley","year":"2013","unstructured":"Emsley R, Chiliza B, Asmal L, Harvey BH. The nature of relapse in schizophrenia. BMC Psychiatry. 2013;8(13):50. https:\/\/doi.org\/10.1186\/1471-244X-13-50.","journal-title":"BMC Psychiatry"},{"key":"976_CR10","first-page":"1019","volume-title":"Pharmacotherapy: a pathophysiologic approach","author":"L Crismon","year":"2014","unstructured":"Crismon L, Argo TR, Buckley PF, et al. Schizophrenia. In: DiPiro JT, Talbert RL, Yee GC, et al., editors. Pharmacotherapy: a pathophysiologic approach. 9th ed. New York: McGraw-Hill; 2014. p. 1019\u201346.","edition":"9"},{"key":"976_CR11","doi-asserted-by":"publisher","DOI":"10.2147\/PROM.S42735","author":"PM Haddad","year":"2014","unstructured":"Haddad PM, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas. 2014. https:\/\/doi.org\/10.2147\/PROM.S42735.","journal-title":"Patient Relat Outcome Meas."},{"key":"976_CR12","doi-asserted-by":"publisher","DOI":"10.9758\/cpn.2018.16.4.361","author":"SC Park","year":"2018","unstructured":"Park SC, Choi MY, Choi J, Park E, Tchoe HJ, Suh JK, et al. Comparative efficacy and safety of long-acting injectable and oral second-generation antipsychotics for the treatment of schizophrenia: a systematic review and meta-analysis. Clin Psychopharmacol Neurosci. 2018. https:\/\/doi.org\/10.9758\/cpn.2018.16.4.361.","journal-title":"Clin Psychopharmacol Neurosci."},{"key":"976_CR13","doi-asserted-by":"publisher","DOI":"10.1708\/3281.32542","author":"P Valsecchi","year":"2019","unstructured":"Valsecchi P, Barlati S, Garozzo A, Deste G, Nibbio G, Turrina C, et al. Paliperidone palmitate in short- and long-term treatment of schizophrenia. Riv Psichiatr. 2019. https:\/\/doi.org\/10.1708\/3281.32542.","journal-title":"Riv Psichiatr"},{"key":"976_CR14","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.MS19053AH5C","author":"CU Correll","year":"2020","unstructured":"Correll CU, Lauriello J. Using long-acting injectable antipsychotics to enhance the potential for recovery in schizophrenia. J Clin Psychiatry. 2020. https:\/\/doi.org\/10.4088\/JCP.MS19053AH5C.","journal-title":"J Clin Psychiatry"},{"key":"976_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0507-x","author":"E Biagi","year":"2017","unstructured":"Biagi E, Capuzzi E, Colmegna F, Mascarini A, Brambilla G, Ornaghi A, et al. Long-acting injectable antipsychotics in schizophrenia: literature review and practical perspective, with a focus on aripiprazole once-monthly. Adv Ther. 2017. https:\/\/doi.org\/10.1007\/s12325-017-0507-x.","journal-title":"Adv Ther"},{"key":"976_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000285","author":"S Pappa","year":"2019","unstructured":"Pappa S, Mason K, Howard E. Long-term effects of paliperidone palmitate on hospital stay and treatment continuation. Int Clin Psychopharmacol. 2019. https:\/\/doi.org\/10.1097\/YIC.0000000000000285.","journal-title":"Int Clin Psychopharmacol"},{"key":"976_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.nsa.2022.100111","author":"J Garc\u00eda-Carmona","year":"2022","unstructured":"Garc\u00eda-Carmona J, Barnett J, Campos-Navarro MP, Mason K, Valdivia-Mu\u00f1oz F, Pappa S. Comparative effectiveness of long-acting injectable antipsychotics in a large naturalistic cohort across two European centres: findings from the long-acting injectable antipsychotics collaborative (LAICO) study. Neurosci Appl. 2022. https:\/\/doi.org\/10.1016\/j.nsa.2022.100111.","journal-title":"Neurosci Appl."},{"key":"976_CR18","doi-asserted-by":"publisher","first-page":"957","DOI":"10.4088\/JCP.13r08440","volume":"74","author":"J Kishimoto","year":"2013","unstructured":"Kishimoto J. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis. J Clin Psychiatry. 2013;74:957\u201365.","journal-title":"J Clin Psychiatry"},{"key":"976_CR19","unstructured":"Joint Formulary Committee. Paliperidone. In: British National Formulary (online). BMJ Group and pharmaceutical Press https:\/\/bnf.nice.org.uk\/drug\/paliperidone. Accessed 20 Feb 2022"},{"key":"976_CR20","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14m09584","author":"L Alphs","year":"2015","unstructured":"Alphs L, Benson C, Cheshire-Kinney K, Lindenmayer JP, Mao L, Rodriguez SC, et al. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study. J Clin Psychiatry. 2015. https:\/\/doi.org\/10.4088\/JCP.14m09584.","journal-title":"J Clin Psychiatry"},{"key":"976_CR21","doi-asserted-by":"publisher","DOI":"10.1177\/2045125320924789","author":"S Pappa","year":"2020","unstructured":"Pappa S, Mason K. Partial compliance with long-acting paliperidone palmitate and impact on hospitalization: a 6-year mirror-image study. Ther Adv Psychopharmacol. 2020. https:\/\/doi.org\/10.1177\/2045125320924789.","journal-title":"Ther Adv Psychopharmacol."},{"issue":"6","key":"976_CR22","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1177\/0018578718809269","volume":"54","author":"K Luther","year":"2019","unstructured":"Luther K, Fung GM, Khorassani F. Cost comparison of atypical antipsychotics: paliperidone ER and risperidone. Hosp Pharm. 2019;54(6):389\u201392. https:\/\/doi.org\/10.1177\/0018578718809269 (Epub 2018 Nov 4. PMID: 31762487; PMCID: PMC6852033).","journal-title":"Hosp Pharm"},{"key":"976_CR23","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/YIC.0000000000000077","volume":"30","author":"D Bressington","year":"2015","unstructured":"Bressington D, Stock J, Hulbert S, MacInnes D. A retrospective observational study of the effectiveness of paliperidone palmitate on acute inpatient hospitalization rates. Int Clin Psychopharmacol. 2015;30:230\u20136.","journal-title":"Int Clin Psychopharmacol"},{"key":"976_CR24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/2045125317753332","volume":"8","author":"PN Deslandes","year":"2018","unstructured":"Deslandes PN, Ward EH, Norris K, Sewell RD. Effectiveness of paliperidone long-acting injection in clinical practice. Ther Adv Psychopharmacol. 2018;8:139\u201345.","journal-title":"Ther Adv Psychopharmacol."},{"key":"976_CR25","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/JCP.0000000000000385","volume":"35","author":"R Whale","year":"2015","unstructured":"Whale R, Pereira M, Cuthbert S, Fialho R. Effectiveness and predictors of continuation of paliperidone palmitate long-acting injection treatment: a 12-month naturalistic cohort study. J Clin Psychopharmacol. 2015;35:591\u20135.","journal-title":"J Clin Psychopharmacol"},{"key":"976_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.eurpsy.2016.04.009","volume":"37","author":"DM Taylor","year":"2016","unstructured":"Taylor DM, Sparshatt A, O\u2019Hagan M, Dzahini O. Effect of paliperidone palmitate on hospitalisation in a naturalistic cohort\u2014a four-year mirror image study. Eur Psychiatry. 2016;37:43\u20138.","journal-title":"Eur Psychiatry"},{"key":"976_CR27","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/YIC.0000000000000155","volume":"32","author":"N Nikoli\u0107","year":"2017","unstructured":"Nikoli\u0107 N, Page N, Akram A, Khan M. The impact of paliperidone palmitate long-acting injection on hospital admissions in a mental health setting. Int Clin Psychopharmacol. 2017;32:95\u2013102.","journal-title":"Int Clin Psychopharmacol"},{"key":"976_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbx176","author":"H Taipale","year":"2018","unstructured":"Taipale H, Meht\u00e4l\u00e4 J, Tanskanen A, Tiihonen J. Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia-a Nationwide study with 20-year follow-up. Schizophr Bull. 2018. https:\/\/doi.org\/10.1093\/schbul\/sbx176.","journal-title":"Schizophr Bull"},{"key":"976_CR29","doi-asserted-by":"publisher","DOI":"10.1177\/20451253211029490","author":"K Mason","year":"2021","unstructured":"Mason K, Barnett J, Pappa S. Effectiveness of 2-year treatment with aripiprazole long-acting injectable and comparison with paliperidone palmitate. Ther Adv Psychopharmacol. 2021. https:\/\/doi.org\/10.1177\/20451253211029490.","journal-title":"Ther Adv Psychopharmacol."},{"key":"976_CR30","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1017\/S0033291717003051","volume":"48","author":"R Patel","year":"2018","unstructured":"Patel R, Chesney E, Taylor M, Taylor D, McGuire P. Is paliperidone palmitate more effective than other long-acting injectable antipsychotics? Psychol Med. 2018;48:1616\u201323.","journal-title":"Psychol Med"},{"key":"976_CR31","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2015.0270","author":"KL Subotnik","year":"2015","unstructured":"Subotnik KL, Casaus LR, Ventura J, Luo JS, Hellemann GS, Gretchen-Doorly D, Marder S, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A Randomized Clinical Trial. JAMA Psychiat. 2015. https:\/\/doi.org\/10.1001\/jamapsychiatry.2015.0270.","journal-title":"JAMA Psychiat"},{"key":"976_CR32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1017\/S1092852913001016","volume":"19","author":"SM Stahl","year":"2014","unstructured":"Stahl SM. Long-acting injectable antipsychotics: shall the last be first? CNS Spectr. 2014;19:3\u20135.","journal-title":"CNS Spectr"},{"key":"976_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17111935","author":"L Samalin","year":"2016","unstructured":"Samalin L, Garnier M, Auclair C, Llorca PM. Clinical decision-making in the treatment of schizophrenia: focus on long-acting injectable antipsychotics. Int J Mol Sci. 2016. https:\/\/doi.org\/10.3390\/ijms17111935.","journal-title":"Int J Mol Sci"},{"key":"976_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s10597-021-00780-2","author":"S Pappa","year":"2021","unstructured":"Pappa S, Barnett J, Gomme S, Iliopoulou A, Moore I, Whitaker M, et al. Shared and supported decision making in medication in a mental health setting: how far have we come? Community Ment Health J. 2021. https:\/\/doi.org\/10.1007\/s10597-021-00780-2.","journal-title":"Community Ment Health J"},{"key":"976_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00861-6","author":"JM Kane","year":"2021","unstructured":"Kane JM, McEvoy JP, Correll CU, Llorca PM. Controversies surrounding the use of long-acting injectable antipsychotic medications for the treatment of patients with schizophrenia. CNS Drugs. 2021. https:\/\/doi.org\/10.1007\/s40263-021-00861-6.","journal-title":"CNS Drugs"},{"key":"976_CR36","doi-asserted-by":"publisher","first-page":"196","DOI":"10.4088\/JCP.08m04427","volume":"70","author":"DM Taylor","year":"2009","unstructured":"Taylor DM, Fischetti C, Sparshatt A, Thomas A, Bishara D, Cornelius V. Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice. J Clin Psychiatry. 2009;70:196\u2013200.","journal-title":"J Clin Psychiatry"},{"key":"976_CR37","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/2045125318767587","volume":"8","author":"S Mace","year":"2018","unstructured":"Mace S, Dzahini O, O\u2019Hagan M, Taylor D. Haloperidol decanoate long-acting injection (HDLAI): results of a 1-year mirror-image study. Ther Adv Psychopharmacol. 2018;8:241\u20139.","journal-title":"Ther Adv Psychopharmacol."},{"key":"976_CR38","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2021.745","author":"SA Pantall","year":"2021","unstructured":"Pantall SA, Pilsbury J, Gan L, Brownell L. A two-year mirror-image study of the effect of treatment with paliperidone and aripiprazole long-acting injections on need for inpatient care and home treatment intervention. BJPsych Open. 2021. https:\/\/doi.org\/10.1192\/bjo.2021.745.","journal-title":"BJPsych Open."},{"issue":"8","key":"976_CR39","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1001\/jamapsychiatry.2015.0270","volume":"72","author":"KL Subotnik","year":"2015","unstructured":"Subotnik KL, Casaus LR, Ventura J, et al. Longacting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A randomized clinical trial. JAMA Psychiat. 2015;72(8):822\u20139.","journal-title":"JAMA Psychiat"},{"issue":"1\u20133","key":"976_CR40","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.schres.2015.08.015","volume":"169","author":"A Schreiner","year":"2015","unstructured":"Schreiner A, Aadamsoo K, Altamura AC. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophr Res. 2015;169(1\u20133):393\u20139.","journal-title":"Schizophr Res"},{"key":"976_CR41","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","volume":"371","author":"RS Kahn","year":"2008","unstructured":"Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371:1085\u201397.","journal-title":"Lancet"},{"issue":"12","key":"976_CR42","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209\u201323.","journal-title":"N Engl J Med"},{"key":"976_CR43","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/acps.12201","volume":"130","author":"A Attard","year":"2014","unstructured":"Attard A, Olofinjana O, Cornelius V, Curtis V, Taylor D. Paliperidone palmitate long-acting injection\u2013prospective year-long follow-up of use in clinical practice. Acta Psychiatr Scand. 2014;130:46\u201351.","journal-title":"Acta Psychiatr Scand"},{"issue":"10","key":"976_CR44","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1176\/ps.62.10.pss6210_1138","volume":"62","author":"M Olfson","year":"2011","unstructured":"Olfson M, Ascher-Svanum H, Faries DE, Marcus SC. Predicting psychiatric hospital admission among adults with schizophrenia. Psychiatr Serv. 2011;62(10):1138\u201345.","journal-title":"Psychiatr Serv"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00976-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-022-00976-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00976-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T16:08:55Z","timestamp":1673280535000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-022-00976-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,10]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["976"],"URL":"https:\/\/doi.org\/10.1007\/s40263-022-00976-4","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,10]]},"assertion":[{"value":"14 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SP was responsible for the study concept and design. SP, JB and KM were responsible for data extraction and statistical analysis. SP, JB and KM were responsible for drafting the manuscript. All authors were responsible for critical revision of the manuscript and have read and approved the final submitted manuscript, and agree to be accountable for the work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"SP has received honoraria as a consultant or speaker from Janssen, Recordati, Sunovion and CNX Therapeutics and an investigator-led research grant from Recordati. JB and KM have nothing to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors received no financial support for the research, authorship and\/or publication of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Approval was obtained by the department for audit and naturalistic research (project number 1295), West London NHS Trust, UK.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All identifiable personal information was removed for privacy protection, thus the requirement for informed consent was waived.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"Data are available on contact with the authors but are not published in any publically available data set.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}